Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease-Need More Evidence. Authors' Reply

被引：0

作者：

Zhao, Jianhui ^{[1
,2
]}

Xue, Erxu ^{[3
]}

Liu, Zhanju ^{[4
]}

Li, Xue ^{[1
,2
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Big Data Hlth Sci, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou, Zhejiang, Peoples R China

[3] Zhejiang Univ, Sir Run Run Shaw Hosp, Nursing Dept, Sch Med, Hangzhou, Zhejiang, Peoples R China

[4] Tongji Univ, Shanghai Peoples Hosp 10, Ctr Inflammatory Bowel Dis Res, Sch Med,Dept Gastroenterol, Shanghai, Peoples R China

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期

基金：

中国国家自然科学基金;

关键词：

SURVIVAL ANALYSIS;

D O I：

10.1111/apt.18303

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1485 / 1486

页数：2

共 50 条

[31] Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply
Lee, Kate E.
Faye, Adam S.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (09) : 1427 - 1428
[32] Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply
Chaparro, M.
Gisbert, J. P.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) : 940 - 941
[33] Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply
Khalili, Hamed
Casey, Kevin
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (07) : 884 - 884
[34] Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply
Mahadevan, U.
Vermeire, S.
Lasch, K.
Abhyankar, B.
Bhayat, F.
Blake, A.
Dubinsky, M.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (03) : 388 - 389
[35] Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply
Simsek, Melek
de Boer, Nanne K. H.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 216 - 217
[36] Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes-Authors' Reply
Swaminathan, Akhilesh
Sparrow, Miles P.
Gearry, Richard B.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (02) : 408 - 409
[37] Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease: Need More Evidence
Hu, Fei-Hong
Chen, Hong-Lin
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (06): : 1101 - 1102
[38] Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply
Hadi, Yousaf
Kochhar, Gursimran S.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (01) : 179 - 179
[39] Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply
Ardabili, Ashkan Rezazadeh
Janssen, Laura
Mujagic, Zlatan
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (11-12) : 1250 - 1251
[40] Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply
Rosiou, Konstantina
Selinger, Christian P.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 898 - 899

← 1 2 3 4 5 →